Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg starts coverage of Xaar at 'buy', shares spark

(Sharecast News) - Berenberg started coverage of Xaar on Friday with a 'buy' rating and 160p price target. It pointed out that Xaar is the only global independent industrial inkjet printhead designer and manufacturer.

"Through recent acquisitions it has broadened its portfolio of associated systems to speed up the integration of its printheads by OEM customers," it said. "It has unique patented technology and production knowledge built up over three decades that differentiates it from its larger Japanese conglomerate competitors."

Berenberg said Xaar's technology is helping to drive the analogue-to-digital conversion of printing processes across multiple new and existing end-markets, helped by its unique ability to inkjet print ultra-high viscosity fluids and inks.

"After several years of external headwinds delaying new end-markets from adopting Xaar's disruptive technology, we now have visibility on the revenue inflection point," the bank said.

Berenberg said recently entered new end-markets are gaining revenue traction.

It noted that Xaar's printheads and inkjet technology is used across five core end-markets: ceramics and glass, coding and marking/direct-to-shape, wide-format graphics and labels, 3D printing and advanced manufacturing, and packaging and textiles.

"The group's legacy end-markets have stabilised in recent quarters, although we do not expect the ceramic tile decoration market to see any recovery until at least FY28E," the bank said.

"Recently entered new end-markets, such as wax printing for jewellery manufacturing and digital printing of textiles, have a strong growth outlook as printing machines recently launched by Xaar's OEM customers gain traction on quick economic payback."

The bank's base case assumes revenue from these two markets grows at a 21% compound annual growth rate FY24-FY29.

At 0822 BST, the shares were up 7.3% at 125.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.